Xeris Pharmaceuticals Stock Discussion

$Xeris Pharmaceuticals(XERS.US)$ Xeris Biopharma Reports Preliminary Q2 Total Revenue To Exceed $47M, Representing Over 23% Growth Over Last Year; Estimate $44.894M

$Xeris Pharmaceuticals(XERS.US)$ And you were doing so lovely! Oh well still a nice PI on fairly benign PR as far as a catalyst for moving up

$Xeris Pharmaceuticals(XERS.US)$ Xeris Biopharma Holdings Inc - FDA End-of-Phase 2 Interaction to Facilitate a Phase 3 Pivotal Study Program Is Expected by Year-End

$Xeris Pharmaceuticals(XERS.US)$
Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)
Xeris Biopharma announced positive topline results from its Phase 2 study of XP-8121, a once-weekly subcutaneous levothyroxine (SC) formulation. The study showed that XP-8121 provides predictable bioavailability and sustained levothyroxine levels, achieving normalized TSH/T4 levels with 45% less drug...

$Xeris Pharmaceuticals(XERS.US)$ Reuters· 1 min ago
Xeris Biopharma: Potential to Get Development Payments, Plus Low Double-Digit Royalties Based on Future Sales of Xeris Glucagon for Pumps, Pump Systems

$Xeris Pharmaceuticals(XERS.US)$Moomoo 24/7· 1 min ago1min
Xeris Biopharma Enters Into An Exclusive Worldwide License Agreement With Amgen For Xeriject Formulation Of Teprotumumab For Thyroid Eye Disease; Xeris Has The Potential To Receive $75M In Development And Regulatory Milestones